The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Bonomelli, Camille ^a   Doores, Katie J ^b,c   Dunlop, D Cameron ^b   Thaney, Victoria ^b   Dwek, Raymond A ^a   Burton, Dennis R ^b,c   Crispin, Max ^a   Scanlan, Christopher N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GLYCAN; MANNOSE OLIGOSACCHARIDE; MONOMER; RECOMBINANT GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 120; MANNOSE; OLIGOSACCHARIDE; POLYSACCHARIDE; RECOMBINANT PROTEIN;

ARTICLE; CELL STRAIN HEK293; CHEMICAL MODIFICATION; CLADISTICS; CONTROLLED STUDY; EMBRYO; FUCOSYLATION; GALACTOSYLATION; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; VIRION; VIROGENESIS; VIRUS ENVELOPE; VIRUS EXPRESSION; VIRUS PARTICLE; CELL CULTURE; CHEMISTRY; CLASSIFICATION; GENETICS; MASS SPECTROMETRY; METABOLISM;

CELLS, CULTURED; GLYCOSYLATION; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MANNOSE; OLIGOSACCHARIDES; POLYSACCHARIDES; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VIRION;

EID: 80051677678     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023521     Document Type: Article

References (46)

1. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, et al. (2010) Molecular Architectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact Viruses: Strain-Dependent Variation in Quaternary Structure. PLoS Pathog 6: e1001249.
2. Pantophlet R, Burton DR, (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769.
3. Scanlan CN, Offer J, Zitzmann N, Dwek RA, (2007) Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446: 1038-1045.
4. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
5. Zhu X, Borchers C, Bienstock RJ, Tomer KB, (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39: 11194-11204.
6. Go EP, Chang Q, Liao HX, Sutherland LL, Alam SM, et al. (2009) Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res 8: 4231-4242.
7. Go EP, Irungu J, Zhang Y, Dalpathado DS, Liao HX, et al. (2008) Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res 7: 1660-1674.
8. Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, et al. (1988) Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. Biochem J 254: 599-603.
9. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, et al. (2009) Essentials of Glycobiology: Cold Spring Harbour Laboratory Press.
10. Kornfeld R, Kornfeld S, (1985) Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54: 631-664.
11. Doores KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, et al. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107: 13800-13805.
12. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, et al. (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76: 7293-7305.
13. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, et al. (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300: 2065-2071.
14. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1,2 mannose residues on the outer face of gp120. J Virol 76: 7306-7321.
15. Dunlop DC, Bonomelli C, Mansab F, Vasiljevic S, Doores KJ, et al. (2010) Polysaccharide mimicry of the epitope of the broadly neutralising anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 20: 812-823.
16. Lee HK, Scanlan CN, Huang CY, Chang AY, Calarese DA, et al. (2004) Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew Chem Int Ed Engl 43: 1000-1003.
17. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
18. Montefiori DC, Mascola JR, (2009) Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS 4: 347-351.
19. Stamatatos L, Morris L, Burton DR, Mascola JR, (2009) Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15: 866-870.
20. Dunlop DC, Ulrich A, Appelmelk BJ, Burton DR, Dwek RA, et al. (2008) Antigenic mimicry of the HIV envelope by AIDS-associated pathogens. AIDS 22: 2214-2217.
21. Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, et al. (2008) An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. J Virol 82: 6447-6457.
22. Luallen RJ, Agrawal-Gamse C, Fu H, Smith DF, Doms RW, et al. (2010) Antibodies against Manα1,2-Manα1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Glycobiology 20: 280-286.
23. Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, et al. (2008) A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol 82: 6359-6368.
24. Kabanova A, Adamo R, Proietti D, Berti F, Tontini M, et al. (2010) Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates. Glycoconj J 27: 501-513.
25. Doores KJ, Fulton Z, Hong V, Patel MK, Scanlan CN, et al. (2010) A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci U S A 107: 17107-17112.
26. Luallen RJ, Fu H, Agrawal-Gamse C, Mboudjeka I, Huang W, et al. (2009) A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol 83: 4861-4870.
27. Scanlan CN, Ritchie GE, Baruah K, Crispin M, Harvey DJ, et al. (2007) Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol 372: 16-22.
28. Balzarini J, (2007) Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 5: 583-597.
29. Bewley CA, Otero-Quintero S, (2001) The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. J Am Chem Soc 123: 3892-3902.
30. Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, et al. (2010) Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401: 236-247.
31. Crooks ET, Tong T, Osawa K, Binley JM, (2011) Enzyme Digests Eliminate Non-Functional Env from HIV-1 Particle Surfaces Leaving Native Env Trimers Intact and Viral Infectivity Unaffected. J Virol.
32. Provine NM, Puryear WB, Wu X, Overbaugh J, Haigwood NL, (2009) The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity. J Virol 83: 9002-9007.
33. Bosshart H, Humphrey J, Deignan E, Davidson J, Drazba J, et al. (1994) The cytoplasmic domain mediates localization of furin to the trans-Golgi network en route to the endosomal/lysosomal system. J Cell Biol 126: 1157-1172.
34. Shapiro J, Sciaky N, Lee J, Bosshart H, Angeletti RH, et al. (1997) Localization of endogenous furin in cultured cell lines. J Histochem Cytochem 45: 3-12.
35. Leaman DP, Kinkead H, Zwick MB, (2010) In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J Virol 84: 3382-3395.
36. Bowden TA, Crispin M, Harvey DJ, Aricescu AR, Grimes JM, et al. (2008) Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. J Virol 82: 11628-11636.
37. Crispin M, Chang VT, Harvey DJ, Dwek RA, Evans EJ, et al. (2009) A human embryonic kidney 293T cell line mutated at the Golgi α-mannosidase II locus. J Biol Chem 284: 21684-21695.
38. Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, et al. (2010) Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology 402: 187-196.
39. Agrawal-Gamse C, Luallen RJ, Liu B, Fu H, Lee FH, et al. (2011) Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J Virol 85: 470-480.
40. Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, et al. (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 84: 5637-5655.
41. Aricescu AR, Lu W, Jones EY, (2006) A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr 62: 1243-1250.
42. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
43. Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, et al. (2009) HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 23: 1659-1667.
44. Rusert P, Fischer M, Joos B, Leemann C, Kuster H, et al. (2004) Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology 326: 113-129.
45. Küster B, Wheeler SF, Hunter AP, Dwek RA, Harvey DJ, (1997) Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal Biochem 250: 82-101.
46. Harvey DJ, Merry AH, Royle L, Campbell MP, Dwek RA, et al. (2009) Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 9: 3796-3801.